Blautia wexlerae (B. wexlerae) is a major acetate producer. The animal experiment has shown that butyrate can improve insulin resistance and reduce fat accumulation. Therefore, this may be one of the mechanisms of B. wexlerae anti-obesity. B. wexlerae has potential for development in the treatment of metabolic diseases. As a leading expert in the field of live biotherapeutic products (LBP) research, Creative Biolabs will be the best choice for your LBP projects.
B. wexlerae cells are Gram-positive, non-spore-forming coccobacilli that are 1.0-1.5×1-3 mm in size. Strictly anaerobic. After 48 h of incubation at 37℃, colonies on Brucella blood agar plates are 1-2 mm in diameter, grey with a white center, umbonate and opaque with entire edges. Grows well anaerobically, but no growth occurs in an atmosphere of 2% or 6% O2. The type of strain, WAL 14507T (=DSM 19850T), was isolated from human faeces. Among the members of the genus Blautia, only B. wexlerae and Blautia luti were ranked in the top 20 bacterial species detected from human faeces by pyrosequencing. B. wexlera contains a high amount of starch (i.e., amylopectin) and produces carbohydrate metabolites (i.e., succinate, lactate, acetate) to consequently modify the gut environment, including the bacterial and SCFA composition of the gut microbiota. Thus, B. wexlerae offers various, numerous, and diverse benefits for health maintenance.
B. wexlerae is a commensal bacterium that is inversely correlated with obesity and type 2 diabetes mellitus. Oral administration of B. wexlerae to mice induced metabolic changes and anti-inflammatory effects that decreased both high-fat diet-induced obesity and diabetes. B. wexlerae's beneficial effects were directly mediated by the production of S-adenosylmethionine, acetylcholine and L-ornithine through its specific amino acid metabolism, and indirectly through carbohydrate metabolism. The discovery of a novel metabolic role of the gut microbiota in the pathophysiology of obesity and T2DM reveals opportunities for the development of new preventive methods (e.g., probiotics) and therapeutic approaches for metabolic disorders.
Fig.1 High-fat diet (HFD)-induced obesity and diabetes were ameliorated by oral administration of B. wexlerae to mice. (Hosomi, 2022)
We supply a variety of B. wexlerae strains of different preservation numbers. If you need other strains, please contact us.
Creative Biolabs is a premier provider of customized solutions to LBP development, we are “LBP Problem-Solvers” focused on delivering best-in-class research and development services. Please feel free to contact us, we welcome the opportunity to discuss the ways we can work with you for B. wexlerae research.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.